Emergent Biosolutions Inc (NYSE:EBS) Director Kathryn C. Zoon sold 1,509 shares of Emergent Biosolutions stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $56.12, for a total transaction of $84,685.08. Following the transaction, the director now owns 21,494 shares of the company’s stock, valued at approximately $1,206,243.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
EBS stock traded up $0.57 during trading on Tuesday, hitting $57.20. The stock had a trading volume of 318,736 shares, compared to its average volume of 466,136. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of 24.55, a price-to-earnings-growth ratio of 0.92 and a beta of 1.56. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.53 and a current ratio of 2.30. The company’s 50 day moving average price is $45.18 and its two-hundred day moving average price is $48.03. Emergent Biosolutions Inc has a 1-year low of $39.11 and a 1-year high of $73.89.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The firm had revenue of $243.20 million for the quarter, compared to analyst estimates of $217.94 million. Emergent Biosolutions had a positive return on equity of 6.68% and a negative net margin of 2.04%. Emergent Biosolutions’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.07 earnings per share. As a group, sell-side analysts forecast that Emergent Biosolutions Inc will post 3.05 earnings per share for the current fiscal year.
Several research firms have recently commented on EBS. Cowen reiterated a “hold” rating and issued a $60.00 price target on shares of Emergent Biosolutions in a research report on Wednesday, July 31st. ValuEngine upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Wednesday, September 4th. Wells Fargo & Co upgraded Emergent Biosolutions from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $61.00 to $64.00 in a research report on Wednesday, September 4th. Chardan Capital set a $71.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Laidlaw set a $72.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a report on Wednesday, September 4th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Emergent Biosolutions has an average rating of “Buy” and a consensus target price of $71.00.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Recommended Story: Why does a company issue an IPO?
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.